Identification of cancer hallmark-associated gene and lncRNA cooperative regulation pairs and dictate lncRNA roles in oral squamous cell carcinoma

Ken Lin1,2,3 | Lin-Jing Song4 | Jing Ma2 | Tie-Song Zhang2 | Ding-Yun You5 | Yong-Wen He6

1Department of Otolaryngology, Head and Neck Surgery, The Affiliated Children’s Hospital of Kunming Medical University, Kunming, China
2Department of Otolaryngology, Head and Neck Surgery, Kunming Children’s Hospital, Kunming, China
3The Affiliated Stomatological Hospital of Kunming Medical University, Kunming, China
4Department of Oncology, Yan’an Hospital, Kunming, China
5School of Public Health, Kunming Medical University, Kunming, China
6Department of Dental Research, The Affiliated Stomatological Hospital of Kunming Medical University, Kunming, China

Abstract

Oral squamous cell carcinoma (OSCC) is the most common malignant tumour in the oral and maxillofacial region. Numerous cancers share ten common traits (“hallmarks”) that govern the transformation of normal cells into cancer cells. Long non-coding RNAs (lncRNAs) are important factors that contribute to tumorigenesis. However, very little is known about the cooperative relationships between lncRNAs and cancer hallmark-associated genes in OSCC. Through integrative analysis of cancer hallmarks, somatic mutations, copy number variants (CNVs) and expression, some OSCC-specific cancer hallmark-associated genes and lncRNAs are identified. A computational framework to identify gene and lncRNA cooperative regulation pairs (GLCRPs) associated with different cancer hallmarks is developed based on the co-expression and co-occurrence of mutations. The distinct and common features of ten cancer hallmarks based on GLCRPs are characterized in OSCC. Cancer hallmark sensitivity to antigrowth signals and self-sufficiency in growth signals are shared by most GLCRPs in OSCC. Some key GLCRPs participate in many cancer hallmarks in OSCC. Cancer hallmark-associated GLCRP networks have complex patterns and specific functions in OSCC. Specially, some key GLCRPs are associated with the prognosis of OSCC patients. In summary, we generate a comprehensive landscape of cancer hallmark-associated GLCRPs that can act as a starting point for future functional explorations, the identification of biomarkers and lncRNA-based targeted therapy in OSCC.
1 | INTRODUCTION

Oral squamous cell carcinoma (OSCC) is the most common malignant tumour in the oral and maxillofacial region, with 4 260 000 new cases arising and ~128 000 deaths occurring annually. The incidence of OSCC has increased in many countries and especially in young people. Many kinds of pathogenic factors, including smoking, alcohol abuse and human papillomavirus infection, all accelerate the tumorigenesis of OSCC. Five-year survival rates for OSCC patients are greater than 80%; however, they drop dramatically to 40% for patients with lymph node involvement and 20% for patients with distant metastasis. The standard treatment for OSCC is surgery, often accompanied by radiotherapy and chemotherapy. There are no effective and reliable biomarkers that predict the aggressiveness or treatment response of OSCC patients.

Long non-coding RNAs (lncRNAs) are a type of non-coding RNA with 200 nucleotides and do not code for proteins. lncRNAs are pervasive across the genome, and dysregulation of their expression is associated with various human diseases including cancer. For example, the lncRNA CTS promotes metastasis in cervical cancer. The lncRNA MYOSLID functions as a competing endogenous RNA to regulate MCL expression by sponging miR-29c-3p in gastric cancer. Some studies have shown that lncRNAs play vital roles in OSCC. For example, the lncRNA SNHG20 promotes the tumorigenesis of OSCC via targeting the miR-197/LIN28 axis. The lncRNA p23154 promotes the invasion-metastasis potential of OSCC by regulating Glut1-mediated glycolysis. The lncRNA PDA3P interacts with miR-185-5p to modulate OSCC progression by targeting Cyclin D2. Moreover, IncRNA and genes can cooperate to fulfil their functions in diseases. Studying the cooperation between genes and lncRNAs is an effective way to predict the roles of IncRNA in disease according to the function of their cooperated genes. For example, IncRNA ANRIL supports proliferation of adult T-Cell leukaemia cells through cooperation with gene EZH2. Zhu et al. analysed an lncRNA and gene co-expression network to identify cycle-related IncRNAs in hepatocellular carcinoma. These kinds of regulatory pairs are named gene and lncRNA cooperative regulation pairs (GLCRPs). However, most studies are only focused on co-expression.

A hallmark is usually defined as “a feature of something that distinguishes it from others.” In 2000, Hanahan and Weinberg proposed six hallmarks of cancer, and in 2011, they extended the cancer hallmarks to a list of ten. They suggest that all kinds of cancer share ten common traits (“hallmarks”) that govern the transformation of normal cells to cancer cells. These hallmarks are ten underlying principles shared by all cancers, which provide a useful framework to understand the remarkable diversity of cancer. However, we have little insight into how to use these hallmarks to depict the roles of lncRNAs and provide biomarkers and treatment for OSCC.

In the present study, an integrated approach is developed to identify GLCRPs associated with cancer hallmarks in OSCC based on mutational and expression data. Some context-specific genes and lncRNAs are discovered in OSCC. We systematically identify and analyse cancer hallmark-associated GLCRPs in OSCC. The genes and lncRNAs in GLCRPs show similar mutation and expression patterns. The distinct and common features for ten cancer hallmarks based on GLCRPs are characterized in OSCC. Some key GLCRPs participate in many cancer hallmarks in OSCC. Cancer hallmark-associated GLCRP networks show complex patterns and specific functions in OSCC. Specifically, some key GLCRPs are associated with the prognosis of OSCC patients. Overall, GLCRPs may accelerate biomarker discovery and therapeutic development in OSCC.

2 | MATERIALS AND METHODS

2.1 | GO terms and genes associated with cancer hallmarks

Cancer hallmark-related GO terms were obtained from a previous study (Table S1). All the genes in these cancer hallmark-related GO terms were downloaded from Gene Ontology using AmiGo. Thus, cancer hallmark-related genes were obtained for subsequent analysis.

2.2 | Mutation and expression profiles of genes and lncRNAs in OSCC

The major mutation data in the present study include somatic mutations and copy number variants (CNVs). We obtained CNV (level 3), somatic mutation (level 3), IncRNA expression and gene expression (level 3) data, as well as clinical data of OSCC patients, from The Cancer Genome Atlas (TCGA, Release: 2017-09-08). The genome annotation data, including genome sites and symbols of genes and lncRNAs, were downloaded from GENCODE 31 (19.06.19). Lastly, 329 tumour and 32 normal control OSCC samples were included in our analysis. The validated data set GSE30784 was downloaded from Gene Expression Omnibus (GEO). The data set included 167 OSCC and 45 normal oral tissues. To filter IncRNA and genes not expressed across all samples, the items with expression values of 0 in all of the samples were excluded. Any remaining expression values...
of 0 were set to the minimum value of all samples, and all values were log2-transformed. All the download links were included in Table S2.

### 2.3 | Identification of OSCC-specific cancer hallmark-related genes and IncRNAs

First, we identified OSCC-specific cancer hallmark-related genes. The genes and IncRNA expression profiles were generated by log transformation to construct expression profiles that followed normal distribution. T-tests were used to calculate the differential expression of all hallmark-related genes between OSCC and normal control samples. The false discovery rate (FDR) was calculated for P-values of the t-tests. The somatic mutation and CNV levels were obtained for each cancer hallmark-related gene in OSCC samples. A cancer hallmark-related gene was considered an OSCC-specific cancer hallmark-related gene if it was differentially expressed (FDR < 0.01) and contained some mutations (CNV or more than three somatic mutations). The OSCC-specific IncRNAs were obtained based on a similar pipeline.

### 2.4 | Identification of GLCRPs in OSCC based on mutation and expression data

We considered that a gene and an IncRNA that cooperated to play their role, called a GLCRP, should show correlations at both the mutation and expression levels. First, Pearson’s correlation coefficients (PCCs) were calculated for each OSCC-specific gene and IncRNA pair. The gene and IncRNA were considered a co-expressed pair if the PCC was higher than 0.3 or smaller than −0.3 and the P-value was smaller than .01. Second, we tested the co-occurrence of mutations for each candidate gene and IncRNA pair. Co-occurrence was considered if there were concurrent mutations in the same samples for genes and IncRNAs. Fisher’s exact test was used to identify co-occurrence gene and IncRNA pairs based on two-by-two contingency tables. For each gene and IncRNA pair, we quantified the number of samples with (a) common mutations, (b) the gene mutation only, (c) the IncRNA mutation only and (d) mutations other than the pair examined. These four values were used to calculate the odds ratio using Fisher’s exact test. The gene and IncRNA pairs were considered co-occurrence pairs if the P-values of Fisher’s exact test were smaller than .01. Thus, GLCRPs for OSCC were identified based on the co-expression and co-occurrence of mutations.

GLCRP networks for each cancer hallmark in OSCC were constructed by Cytoscape 3.3.0 (http://www.cytoscape.org/). The degree analysis of each network was also performed using Cytoscape 3.3.0.

### 2.5 | Survival analysis for the GLCRP in each cancer hallmark for OSCC

We used the regression coefficient of genes and IncRNAs in the cancer hallmark-related GLCRPs related to patient survival based on gene and IncRNA expression data to verify if these cancer hallmark-related GLCRPs were associated with survival. First, we randomly divided the OSCC patient samples into two independent groups. Second, a multivariate Cox regression model was performed for genes and IncRNA in each GLCRP to obtain a standardized Cox regression coefficient for the first group. Some confounders, including age, cancer stage and sex, were also considered in this process. A risk-score formula was established for each OSCC patient based on the expression values of the genes and IncRNAs for the held-out group weighted by their estimated regression coefficients, following the above multivariate Cox regression analysis. Performing Cox regression analysis and validating the model in two independent data sets are helpful for avoiding overfitting. Third, the OSCC patients were divided into high- and low-risk groups based on the median of the risk score as the threshold value. Finally, we performed Kaplan-Meier survival analysis for the high- and low-risk groups. The statistical significance was assessed using the log-rank test. Cancer hallmark-related GLCRPs were significantly associated with survival when P-value <.05. All analyses are performed within the R 3.3.3 framework.

### 3 | RESULTS

#### 3.1 | Some context-specific genes and IncRNAs based on cancer hallmarks were discovered in OSCC

To identify OSCC-specific cancer hallmark-related genes and IncRNAs, we considered both the expression and mutation levels of genes and IncRNAs in OSCC patients. For each cancer hallmark, there were 44.44%-70.83% differentially expressed genes (Figure 1A). The cancer hallmark limitless replicative potential had the most differential genes in all cancer hallmarks (70.83%). The regulation directions, including up- and down-regulated differential genes in cancer hallmarks, were diverse (Figure 1B). Most differential genes were up-regulated in all kinds of cancer hallmarks for OSCC patients. We largely considered two kinds of mutation, point somatic mutations and CNVs, in OSCC. We considered a gene to be a mutated gene in OSCC if somatic mutations occurred in more than three samples or CNVs in more than one sample. The numbers of samples with somatic mutations were concentrated around ten for mutated genes in each cancer hallmark (Figure 1C). There were some mutated genes with high somatic mutation frequencies. For example, in the FAT1 gene, somatic mutation occurred in 32.52% of OSCC samples (Figure 1D). The mutation frequency of CNV was concentrated on 100 for each cancer hallmark in OSCC (Figure 1E). The density distributions of somatic mutations and CNVs were focused on diverse regions in OSCC (Figure 1F). The mutation frequency of CNV was significantly improved relative to the somatic mutations for each cancer hallmark in OSCC (Figure 1G). We extract the OSCC-specific cancer hallmark-related genes if the genes were both differentially expressed and mutated genes. There were 16-661 OSCC-specific genes in diverse cancer hallmarks (Figure 1H). OSCC-specific IncRNAs were also identified. There were 21.77%
differential lncRNAs, and most of them were up-regulated in OSCC (Figure 1I). There were 21.78% lncRNAs with somatic mutations or CNV (Figure 1J). Similar to genes, the frequency of CNV in lncRNAs was higher than that of somatic mutations.

3.2 | Systematic identification of cancer hallmark-associated GLCRPs in OSCC

GLCRPs were identified based on the co-expression and co-occurrence of mutations (see Section 2). We identified some GLCRPs for ten cancer hallmarks in OSCC (Figure 2A). The cancer hallmark insensitivity to antigrowth signals had the most GLCRPs (1295). Fewer genes cooperated with more lncRNAs to play their roles in cancer hallmarks. For example, 99 OSCC-specific genes cooperated with 544 lncRNAs to form 1236 GLCRPs in the cancer hallmark self-sufficiency in growth signals. The correlations between genes and lncRNAs in GLCRPs for each cancer hallmark were strong (Figure 2B, Table S3). The average PCC absolute value for GLCRPs in most cancer hallmarks was approximately 0.4. Moreover, the genes and lncRNAs in GLCRPs also showed strong co-occurrence of mutations. For example, in the cancer hallmark genome instability and mutation, the gene SMC1B and lncRNA MIR9-3HG showed both strong co-expression (PCC = 0.76) and co-occurrence (P-value = 0.008) of mutations in OSCC. The results indicate that the partnerships of genes and lncRNAs in GLCRPs are seen at the mutation and expression levels.

3.3 | The common and specific features of GLCRPs for cancer hallmarks in OSCC

The common GLCRPs between any two kinds of cancer hallmarks are used to characterize the common and distinct features of cancer hallmarks in OSCC. We discover that some cancer hallmarks share a large number of GLCRPs; however, the opposite is the case in some other cancer hallmarks (Figure 3A). For example, the cancer hallmarks self-sufficiency in growth signals and insensitivity to antigrowth signals significantly (P-value < .01) shared common GLCRPs in OSCC (Figure 3B, Table S4). Cancer hallmark genome instability and mutation and reprogramming energy metabolism also significantly (P-value < .01) shared common GLCRPs in OSCC (Table S4). The core genes of these two common network are FGF17 and RBX1. However, there were no common GLCRPs between the cancer hallmark reprogramming energy metabolism and any other cancer hallmarks in OSCC. Two common GLCRP networks between self-sufficiency in growth signals and insensitivity to antigrowth signals and reprogramming energy metabolism and genome instability and mutation were constructed (Figure 3C). Some GLCRPs that participate in multiple cancer hallmarks were discovered (Figure 3D). For example, the GLCRP including the IncRNA LINC00623 and the gene PTK2B participated in four cancer hallmarks, including evading apoptosis, insensitivity to antigrowth signals, self-sufficiency in growth signals and sustained angiogenesis. The lncRNAs and genes in these GLCRPs that participated in multiple cancer hallmarks were all mutated in many OSCC samples (Figure 3E). These genes and lncRNAs were significantly differentially expressed in OSCC samples (Figure 3F). For example, the lncRNA AC007611.1 and the gene KIR2DL4 were all down-regulated in OSCC samples (Figure 3G). All the results indicated that cancer hallmarks show common and specific features of GLCRPs in OSCC. The corresponding relations of lncRNA name and Ensembl ID were shown in Table S5.

3.4 | Cancer hallmark-associated GLCRP networks show complex patterns and specific functions in OSCC

To further depict the features of GLCRPs for each cancer hallmark in OSCC, we constructed five cancer hallmark-associated GLCRP networks. All the networks showed that fewer genes cooperated with multiple lncRNAs in OSCC (Figure S1). All the degree distributions showed a scale-free network structure and indicated that these networks were significant biological networks (Figure 4A). The $R^2$ values of five associated cancer hallmarks were .616, .731, .763, .694 and .738. The cancer hallmark insensitivity to antigrowth signals GLCRP network had the most nodes and edges. The gene GNRH1 had the highest degree (74), and a GNRH1 related sub-network was extracted from the global cancer hallmark insensitivity to antigrowth signals GLCRP network (Figure 4B). The gene GNRH1 and lncRNA LINC01355 showed strong co-expression (PCC = 0.75, Figure 4C). For all the cancer hallmark-associated GLCRP networks, 53.69% of lncRNAs cooperated with more than four genes in OSCC (Figure 4D). The top ten lncRNAs, including AL133215.2, LINC01534, AC092171.4, LINC02560, SNHG15 and so on, with
the highest frequency in all the networks are shown (Figure 4E). The IncRNAs AC006033.2, LINC00426, AL158835.1, AL590438.1, SNHG15, AL591468.1, AC034199.1, AC079209.1 and AL137191.1 cooperated with 2, 1, 14, 9, 3, 10 and 1 genes in the cancer hallmarks evading apoptosis, evading immune detection, insensitivity to antigrowth signals, self-sufficiency in growth signals, sustained angiogenesis, tissue invasion and metastasis and tumour-promoting inflammation. This result indicates that some IncRNAs play essential roles in cancer hallmark-associated GLCRP networks for OSCC.

3.5 | Prognostic benefits of cancer hallmark-associated GLCRPs in OSCC

To evaluate the potential value of GLCRPs as prognostic biomarkers in OSCC, we developed a risk-score formula according to the expression of the gene and IncRNA expression in each GLCRP to generate OS (overall survival) prediction (see Section 2). The median value of risk scores is considered a cut-off point to test the survival of OSCC patients. The OSCC patients were divided into high- and low-risk groups based on the above risk scores. In
FIGURE 3 Common and specific features for any two cancer hallmarks based on GLCRPs in OSCC. A, The chart shows the common GLCRPs between any two cancer hallmarks. The darker colour represents more common GLCRPs. B, The Venn diagrams show the intersection of two cancer hallmarks. C, The two networks show the common GLCRPs in OSCC. D, The GLCRPs for OSCC that appeared in multiple cancer hallmarks. E, The darker colour represents more mutations in lncRNAs and genes in OSCC. F, The point plot shows some GLCRPs with corresponding P-values of differentially expressed genes and lncRNAs. G, The violin plots show the expression of AC007611.1 and KIR2DL4
total, 365 (9.1% of all GLCRPs in all hallmarks) GLCRPs were significantly associated with survival in OSCC patients. In five cancer hallmarks, some GLCRPs were significantly related with survival and could be used as candidate prognostic biomarkers (Figure 5A). Moreover, OSCC patients in the high-risk group had significantly shorter median OS than those in the low-risk group. The OSCC patients were grouped based on the risk scores of these GLCRPs (Figure 5C,D). The results show that some GLCRPs could collectively influence OSCC patient survival and maybe act as specific prognostic biomarkers.

4 | DISCUSSION

The present study provides novel insights into the mechanism and treatment of OSCC by exploring the functional significance and molecular mechanism of GLCRPs associated with cancer hallmarks following expression pattern, somatic mutation and CNV data. Accumulating evidence has shown that many lncRNAs contribute to cancer hallmarks.27,28 The cancer hallmark-based method is assigned to explore the roles of lncRNAs in OSCC, and this kind of method is used to identify driver genes in other cancers.29,30 In our analysis, we identified some key GLCRPs for each cancer hallmark in OSCC. In addition, the common and specific features for any two kinds of cancer hallmarks were analysed based on GLCRPs. There are 1050 common GLCRPs between the cancer hallmarks insensitivity to antigrowth signals and self-sufficiency in growth signals. These two cancer hallmarks are both related to tumour growth. The hallmark-associated GLCRPs generated in this study could facilitate the experimental exploration of lncRNAs in cancer pathogenesis.

Our results demonstrate that the genes and lncRNAs in GLCRPs show strong association on both the mutation and expression levels. The recent application of massively parallel next-generation sequencing to a growing number of cancer genomes has revealed abundant mutually co-occurring genetic alteration events.31-33 Co-occurrence of mutations indicates that two genes (or other molecules) maybe cooperate to play their roles. Co-occurrence of mutations is a common and informative phenomenon during cancerogenesis, which helps to uncover novel drivers, decipher their downstream functions and even provide novel treatment methods.
in cancer. For example, PC9 lung adenocarcinoma cells harbour an activating EGFR exon 19 in-frame deletion and are naturally sensitive to the EGFR inhibitor erlotinib. Variants such as mutant KRAS that re-activate downstream signalling pathways can rescue the erlotinib-induced lethality in this cell type.34 In addition, previous study also used the method which lncRNAs were mutually exclusive
with well-known cancer driver genes to distinguish driver IncRNAs from passengers. In the present study, the co-occurrence of mutations was used to explore the cooperative mechanism of genes and IncRNAs in OSCC. This provides us with important implications in the functional exploration of IncRNAs in cancer pathogenesis. Survival analyses were also performed for GLCRPs associated with cancer hallmarks in OSCC based on an integrative approach. The integration of two genes for analysing survival has been applied in studies about ceRNAs in cancer. We improved the integrated survival analysis method by randomly dividing the OSCC patients into two independent groups. One group was used for training coefficients of genes and IncRNAs associated with prognosis. The other group was used to obtain risk scores based on the above coefficients and to perform survival analysis. This improved approach avoided the overfitting phenomenon. There are 365 prognosis-associated GLCRPs that were identified in OSCC and could be candidate prognostic biomarkers for OSCC. In addition, we performed the process of survival analysis for 100 times and these 365 prognosis-associated GLCRPs were still significant at least 70 times. Although TCGA data set included large sample size, the results indicated that our analysis was reliable. The data of TCGA are updated constantly, and future work could focus on further validating GLCRPs using updated TCGA data sets or more samples. In addition, more computational methods about differential and co-expressed analysis for gene and IncRNA should be added to improve the results.

Overall, some OSCC-specific cancer hallmark-associated genes and IncRNAs were identified. Based on these OSCC-specific cancer hallmark-associated genes and IncRNAs, some GLCRPs were discovered following the co-expression and co-occurrence of mutations. Common and specific features for any two cancer hallmarks were depicted in OSCC based on GLCRPs. GLCRP networks for each cancer hallmark were constructed and analysed in OSCC. Survival analyses indicated that GLCRPs could be potential prognostic biomarkers for OSCC. In summary, our study leads to a novel starting point for future functional explorations, the identification of biomarkers and IncRNA-based targeted therapy for OSCC.

CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest.

AUTHOR CONTRIBUTIONS
HYW and YDY conceived and designed the experiments; LK, SLJ, MJ and ZTS analysed the data; and LK and SLJ wrote the manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Ding-Yun You https://orcid.org/0000-0002-3830-1891

REFERENCES
1. Zhong LP, Zhang CP, Ren GX, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31:744-751.
2. Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol. 2006;7:77-82.
3. Muller S, Pan Y, Li R, Chi AC. Changing trends in oral squamous cell carcinoma with particular reference to young patients: 1971-2006. The Emory University experience. Head Neck Pathol. 2008;2:60-66.
4. Ha A, Kujan O, Farah CS. The utility of oral brush cytology in the early detection of oral cancer and oral potentially malignant disorders: a systematic review. J Oral Pathol Med. 2018;47:104-116.
5. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E386.
6. Dissanayaka WL, Pitiyage G, Kumarasiri PV, Liyanage RL, Dias KD, Tilakaratne WM. Clinical and histopathologic parameters in survival of oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:518-525.
7. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52:195-215.
8. Glenny AM, Furness S, Worthington HV, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. Cochrane Database Syst Rev. 2010;CD006387.
9. St Laurent G, Wahlestedt C, Kapranov P. The Landscape of long noncoding RNA classification. Trends Genet. 2015;31:239-251.
10. Hua JT, Ahmed M, Guo H, et al. Risk SNP-mediated promoter-enhancer switching drives prostate cancer through IncRNA PCAT19. Cell. 2018;174:564-575.e18.
11. Panir K, Schjenken JE, Robertson SA, Hull ML. Non-coding RNAs in endometriosis: a narrative review. Hum Reprod Update. 2018;24:497-515.
12. Wang S, Liang K, Hu Q, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017;127:4498-4515.
13. Feng S, Liu W, Bai X, et al. LncRNA-CTS promotes metastasis and epithelial-to-mesenchymal transition through regulating miR-505/ZEB2 axis in cervical cancer. Cancer Lett. 2019;465:105-117.
14. Han Y, Wu N, Jiang M, et al. Long non-coding RNA MYOSLID functions as a competing endogenous RNA to regulate MCL-1 expression by sponging miR-29c-3p in gastric cancer. Cell Prolif. 2019;52:e12678.
15. Wu J, Zhao W, Wang Z, Xiang X, Zhang S, Liu L. Long non-coding RNA SNHG20 promotes the tumorigenesis of oral squamous cell carcinoma via targeting miR-197/LIN28 axis. J Cell Mol Med. 2019;23:680-688.
16. Wang Y, Zhang X, Wang Z, et al. LncRNA-p231545 promotes the invasion-metastasis potential of oral squamous cell carcinoma by regulating Glut1-mediated glycolysis. Cancer Lett. 2018;434:172-183.
17. Sun CC, Zhang L, Li G, et al. The IncRNA PDA13P interacts with miR-185-5p to modulate oral squamous cell carcinoma progression by targeting cyclin D2. Mol Ther Nucleic Acids. 2017;9:100-110.
18. Li D, Li F, Jiang K, et al. Integrative analysis of long noncoding RNA and mRNA reveals candidate IncRNAs responsible for meat quality at different physiological stages in Gushi chicken. PLoS ONE. 2019;14:e0215006.
19. Song Z, Wu W, Chen M, et al. Long noncoding RNA ANRIL supports proliferation of adult T-cell leukemia cells through cooperation with EZH2. J Virol. 2018;92.
20. Jin L, Hu S, Tu T, et al. Global long noncoding RNA and mRNA expression changes between prenatal and neonatal lung tissue in pigs. Genes (Basel). 2018;9. https://doi.org/10.3390/genes9090443

21. Zhu HR, Yu XN, Zhang GC, et al. Comprehensive analysis of long noncoding RNA/messenger RNA/microRNA coexpression network identifies cell cycle-related IncRNA in hepatocellular carcinoma. Int J Mol Med. 2019;44(5):1844-1854.

22. Lazebnik Y. What are the hallmarks of cancer? Nat Rev Cancer. 2010;10:232-233.

23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.

24. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.

25. Plaisier CL, Pan M, Baliga NS. A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. Genome Res. 2012;22:2302-2314.

26. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S. AmiGO: online access to ontology and annotation data. Bioinformatics. 2009;25:288-289.

27. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965-3981.

28. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452-463.

29. Gao S, Tibiche C, Zou J, et al. Identification and construction of combinatorial cancer hallmark-based gene signature sets to predict recurrence and chemotherapy benefit in stage II colorectal cancer. JAMA Oncol. 2016;2:37-45.

30. Yother G, Song N, George TJ Jr. Cancer hallmark-based gene sets and personalized medicine for patients with stage II colon cancer. JAMA Oncol. 2016;2:23-24.

31. Iyer G, Al-Ahmadie H, Schultz N, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol. 2013;31:3133-3140.

32. Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61:673-684.

33. Lim KP, Yip SP, Cheung SC, Leung KW, Lam ST, To CH. Novel PRPF31 and PRPH2 mutations and co-occurrence of PRPF31 and RHO mutations in Chinese patients with retinitis pigmentosa. Arch Ophthalmol. 2009;127:784-790.

34. Berger AH, Brooks AN, Wu X, et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell. 2017;32:884.

35. Deng Y, Luo S, Zhang X, et al. A pan-cancer atlas of cancer hallmark-associated candidate driver IncRNAs. Mol Oncol. 2018;12:1980-2005.

36. Wang P, Ning S, Zhang Y, et al. Identification of IncRNA-associated competing triplets reveals global patterns and prognostic markers for cancer. Nucleic Acids Res. 2015;43:3478-3489.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Lin K, Song L-J, Ma J, Zhang T-S, You D-Y, He Y-W. Identification of cancer hallmark-associated gene and IncRNA cooperative regulation pairs and dictate IncRNA roles in oral squamous cell carcinoma. J Cell Mol Med. 2020;24:5213–5223. https://doi.org/10.1111/jcmm.15174